BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
Personalized medicine
,
Acetaminophen
,
rs2230926
,
CYP51
,
calcium channel activity
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
17, 20-lyase
Summary
General Info
Curated Studies
Most Correlated Studies
Adrenocortical cancer NCI-H295A cells treated with 8-Br-cAMP
Explore Curated Studies Results
Literature
Most Relevant Literature
Effect of the spatial-temporal specific theca cell Cyp17 overexpression on the reproductive phenotyp…
Aberrant H19 Expression Disrupts Ovarian Cyp17 and Testosterone Production and Is Associated with Po…
Targeting the adrenal gland in castration-resistant prostate cancer: a case for orteronel, a selecti…
Effect of a novel 17,20-lyase inhibitor, orteronel (TAK-700), on androgen synthesis in male rats.
Homozygous CYP17A1 mutation (H373L) identified in a 46,XX female with combined 17α-hydroxylase/17,20…
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
Evaluation of a Treatment With Allopurinol in Adenylosuccinate Lyase Deficiency
Gene Expression in Patients With Metastatic Prostate Cancer Receiving CYP-17 Inhibition Therapy
Mutation Analysis of 17α-Hydroxylase
Phase Ib/II Study Evaluating Orteronel (Without Prednisone) Combined With Itraconazole In Men With C…
Orteronel (TAK-700) in Metastatic or Advanced Non-resectable Granulosa Cell Ovarian Tumors. The Grek…
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ